Skip to main content
Premium Trial:

Request an Annual Quote

Sitting Pretty

Premium

As genomics stocks bottom out, here’s who’s still on top

$7.1M William Rich, Ciphergen, CEO

$63.1M Mark Chandler, Luminex, CEO

$213.3M Lyle Turner, Invitrogen, CEO

$2.7M Mark Boguski, Rosetta Inpharmatics, Sr. VP of R&D

$6.9M William Matthews, Deltagen, CEO

$4.9M Mark Gessler, Gene Logic, CEO

$1.8M Stuart Collinson, Aurora Biosciences, CEO

$8.7M Howard Birndorf, Nanogen, CEO

$66.8M Mark Chee, Illumina, VP of Genomics

$76.0M Tony White, Applera, CEO

$5.3M Arthur sands, Lexicon Genetics, CEO

$6.3M Gregg Helt, Affymetrix, Principal Scientist

$1.3M Dale Pfost, Orchid BioSciences, President and CEO

$8.4M Cyrus Harmon, Affymetrix, VP of Computational Genomics

$1.7M John King, Rosetta Inpharmatics, COO

$9.7M Timothy Rink, Aurora Biosciences, Fmr. Chrm. and CEO

$40.5M Michael Hunkapiller, Applied Biosystems, President

$2.6M Tony Shuh, Sequenom, President and CEO

$4.1M Daniel Kisner, Caliper Technologies, CEO

$8.5M Stephen Fodor, Affymetrix, CEO

$1.1M Kieran Gallahue, Nanogen, CFO

$17.1M Roy Whitfield, Incyte Genomics, CEO

$42.2M Craig Venter, Celera Genomics, CSO

$15.3M Harden McConnell, Molecular Devices, Founder

$3.2M Calvin Chow, Caliper Technologies, COO

$3.9M Hannes Smarason, DeCode Genetics, Sr. Bus. & Finance Officer

$4.8M Joseph Keegan, Molecular Devices, CEO

$14.6M Emery Olcott, Packard Bioscience, CEO

$4.9M Joseph Limber, Aclara BioSciences, CEO

$18.4M Dennis Winger, Applied Biosystems, CFO

$2.9M Herbert Hooper, Aclara BioSciences, CSO

$38.8M Jeffrey Williams, Genomic Solutions, CEO

$21.9M Kari Stefansson, DeCode Genetics, CEO

$7.2M Jay Flatley, Illumina, CEO

$8.8M Randy Scott, Incyte Genomics, Chairman

$10.0M Richard McKernan, Packard BioScience, Sr. VP

$3.4M Jeffrey Gulcher, DeCode Genetics, VP, R&D

$5.9M Stephan Friend, Rosetta Inpharmatics, CEO

Values reflect individuals’ fully diluted company shares and options. All data based on most recent SEC filings available and March 29 share prices.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.